Dataset from A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection

The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.The secondary objectives of the study are:* To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo* To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo* To assess the concentrations of REGN10933 and REGN10987 in serum over time* To assess the immunogenicity of REGN10933 and REGN10987